New Directions for SMA Therapy
AbstractSpinal muscular atrophy (SMA) is a severe disorder of motor neurons and the most frequent genetic cause of mortality in childhood, due to respiratory complications. The disease occurs due to mutations in the survival motor neuron 1 (SMN1) gene that leads to a reduction in the SMN protein, causing degeneration of lower motor neurons, muscle weakness and atrophy. Recently, the Food and Drug Administration (FDA) and the European Medical Agency (EMA) approved the antisense oligonucleotide nusinersen, the first disease-modifying treatment for SMA. Encouraging results from SMN1 gene therapy studies have raised hope for other therapeutic approaches that might arise in the coming years. However, nusinersen licensing has created ethical, medical, and financial implications that will need to be addressed. In this review, the history and challenges of the new SMA therapeutic strategies are highlighted. View Full-Text
Share & Cite This Article
Messina, S. New Directions for SMA Therapy. J. Clin. Med. 2018, 7, 251.
Messina S. New Directions for SMA Therapy. Journal of Clinical Medicine. 2018; 7(9):251.Chicago/Turabian Style
Messina, Sonia. 2018. "New Directions for SMA Therapy." J. Clin. Med. 7, no. 9: 251.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.